Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Sunitinib in the Expression of VEGF and of Interleukin 8: Explanation of Anti-angiogenic Effects.

Trial Profile

Effects of Sunitinib in the Expression of VEGF and of Interleukin 8: Explanation of Anti-angiogenic Effects.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms SUVEGIL
  • Most Recent Events

    • 22 Mar 2018 Results assessing effect of angiogenic treatment on VE cadherin post translational modifications using patient data from SUVEGIL and TORAVA trials published in the British Journal of Cancer
    • 29 Aug 2017 Results (n=99) of SUVEGIL and TORAVA trials ,published in the British Journal of Cancer.
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top